Josephus Buijs
Adjunct senior lecturer at Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Marika Nestor
- E-mail:
- jos.buijs@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
More information is available to staff who log in.
Short presentation
Jos Buijs is CEO of Ridgeview Instruments AB and affiliated with the research group of Prof. Nestor at the Department of Immunology, Genetics and Pathology of Uppsala University.
At Ridgeview, we develop instruments and software to study biological interactions on live cells. At the same time, we apply these tools in research in the cell biology area with focus on the development of therapeutic antibodies, medical imaging and radio-immunotherapy.
Keywords
- biophysics
- cell analysis
- fluorescent probes
Publications
Recent publications
- Repurposing the mammalian RNA-binding protein Musashi-1 as an allosteric translation repressor in bacteria (2024)
- Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength (2021)
- Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta (2021)
- A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells (2020)
- Carbon Flux as a Measure of Prostate Cancer Aggressiveness (2020)
All publications
Articles
- Repurposing the mammalian RNA-binding protein Musashi-1 as an allosteric translation repressor in bacteria (2024)
- Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength (2021)
- Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta (2021)
- A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells (2020)
- Carbon Flux as a Measure of Prostate Cancer Aggressiveness (2020)
- Pilot-scale process for magnetic bead purification of antibodies directly from non-clarified CHO cell culture (2019)
- Comparative Evaluation of Two DARPin Variants (2019)
- Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours (2019)
- Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe (2018)
- Radionuclide tumor targeting using ADAPT scaffold proteins (2018)
- New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies (2018)
- Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation (2018)
- Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells (2017)
- Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells (2017)
- The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule (2017)
- Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m (2017)
- Evaluation of Affibody Molecules for Radionuclide Imaging of Carbonic Abhydrase IX Expression In Vivo (2016)
- Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX (2016)
- Surface plasmon resonance biosensing (2016)
- The use of radiocobalt as a label improves PET imaging of EGFR using DOTA-conjugated affibody molecules (2015)
- ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers (2015)
- Degree of Bivalent Binding correlates with C1q Binding Strength for CD20 Antibodies Rituximab, Ofatumumab, and Obinituzumab.
- Bivalent Binding on Cells varies between CD20 Antibodies and is Dose-dependent
